Krystal Biotech (KRYS) Restructuring Costs (2022 - 2024)

Krystal Biotech (KRYS) has 3 years of Restructuring Costs data on file, last reported at $12.5 million in Q3 2024.

• For the quarter ending Q3 2024, Restructuring Costs changed N/A year-over-year to $12.5 million; the trailing twelve-month figure through Jun 2025 stood at $12.5 million (down 88.89% YoY), and the FY2024 full-year result was $37.5 million, up 200.0% from the prior year.
• Restructuring Costs retreated to $12.5 million in Q3 2024, from $37.5 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $37.5 million in Q4 2023 to a low of $12.5 million in Q1 2023.
• A 3-year average of $25.0 million and a median of $25.0 million in 2022 frame the typical range for Restructuring Costs.
• Across the five-year window, Restructuring Costs slumped 50.0% in 2023 and surged 200.0% in 2024, its largest moves.
• Tracing KRYS's Restructuring Costs over 3 years: stood at $25.0 million in 2022, then jumped by 50.0% to $37.5 million in 2023, then tumbled by 66.67% to $12.5 million in 2024.
• Business Quant data shows KRYS's Restructuring Costs at $12.5 million in Q3 2024, $37.5 million in Q2 2024, and $37.5 million in Q1 2024.